Standard BioTools (LAB) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

LAB Standard BioTools

Watchlist

1.620
+0.010+0.62%

Close Nov 21 16:00 ET

603.06MMarket Cap-2347P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Life Sciences Stocks Viewed Positively at TD Cowen Despite Post-election Weakness
Seeking AlphaNov 15 15:55 ET
Express News | Standard BioTools - Alex Kim Will No Longer Serve as Co’s Chief Operating Officer, & Co Will Vacate Position of Chief Operating Officer
ReutersNov 7 08:09 ET
Express News | Standard BioTools Appoints Alex Kim as Chief Financial Officer
ReutersNov 7 08:00 ET
Press Release: Standard BioTools Appoints Alex Kim as Chief Financial Officer
Dow JonesNov 7 08:00 ET
Standard BioTools | 10-Q: Q3 2024 Earnings Report
SECNov 6 17:22 ET · Announcements
Earnings Release: Here's Why Analysts Cut Their Standard BioTools Inc. (NASDAQ:LAB) Price Target To US$3.17
Yahoo FinanceNov 2 09:06 ET

Comments

Jaguar8

Sep 24 07:04

NEWS

$Standard BioTools (LAB.US)$
Standard BioTools Achieves New Record of the Most Protein Measurements on the Most Sample Types with Expansion of the SomaScan® 11K Platform
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), today announced that the SomaScan® 11K Platform now includes protein measurements on a broader range of sample types, including cerebrospinal fluid (CSF), aqueous humor, tissue homogenates and cell lysates. The SomaScan® Platf...

MARKET-TEST-DUMMY

Jul 25 09:18

Insider buying

$Standard BioTools (LAB.US)$

MARKET-TEST-DUMMY

Jun 5 15:13

Keep trying

$Standard BioTools (LAB.US)$

Trytosaveabit

May 28 15:05

Hmm

$Standard BioTools (LAB.US)$ Standard BioTools Purchases the Carterra® Lsa-Xt System to Accelerate Data Delivery and Provide Greater Validation to Somascan Customers

Trytosaveabit

May 8 15:23

Decent

$Standard BioTools (LAB.US)$ Revenue was $46 million, up 81% year-over-year, with impact of SomaScan
assay services, kits and related revenue in 2024; and
-- Ended the quarter with cash, cash equivalents, restricted cash and
short-term investments of $464 million, after accounting for $71 million
cash payments for merger-related expenses, settlement of year-end
operating accruals, debt retirement and completed stock buybacks.

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

LAB Standard BioTools

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target